Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026)

Bicara Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $323.5 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 30.0% year-over-year to $323.5 million; the TTM figure through Mar 2026 stood at $323.5 million (down 30.0% YoY), while the FY2025 annual figure was $96.7 million, down 80.26% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $323.5 million, up from $96.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $520.8 million in Q3 2024, with the low at $96.7 million in Q4 2025.
• The 4-year median for Cash & Equivalents is $380.0 million (2025), against an average of $341.4 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 112.51% in 2024, then plunged 80.26% in 2025.
• Bicara Therapeutics' Cash & Equivalents stood at $230.4 million in 2023, then surged by 112.51% to $489.7 million in 2024, then slumped by 80.26% to $96.7 million in 2025, then jumped by 234.55% to $323.5 million in 2026.
• Business Quant data shows BCAX's Cash & Equivalents at $323.5 million in Q1 2026, $96.7 million in Q4 2025, and $171.7 million in Q3 2025.